share_log

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $45

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $45

b of A Securities維持對bridgebio pharma的買入評級,將目標股價上調至45美元
Benzinga ·  2024/11/25 21:10  · 評級/大行評級

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $42 to $45.

美銀證券分析師Geoff Meacham維持bridgebio pharma(納斯達克:BBIO)的買入評級,並將目標價格從42美元上調至45美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論